Notícias UroGen Pharma Ltd - URGN | Ações NASDAQ | ADVFN Brasil

Índice Bovespa

US Dollar vs BRL

Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
UroGen Pharma Ltd (URGN)
UroGen Pharma Ltd (URGN) Notícias

UroGen Pharma Ltd (URGN)

11,91

0,36

(3,12%)

Fechado 24 Novembro 6:00PM

Atrasado por 15 minutos

11,91

-0,01

(-0,08%)

Após o horário de negociação: 9:25PM

Atrasado por 15 minutos

Ferramentas de nível profissional para investidores individuais.

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025

UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation Conference

UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024

ENVISION Trial Results Published in the Journal of Urology Report 82.3% Duration of Response 12 Months after Achieving Complete Response for UGN-102, Potentially First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC

UroGen Announces FDA Acceptance of its New Drug Application for UGN-102

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

UroGen Appoints Chris Degnan as Chief Financial Officer

First Patient Dosed in Phase 3 Clinical Trial of UGN-103, a Next Generation Mitomycin-Based Formulation in Development for the Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Form 8-K - Current report

UroGen Receives New U.S. Patent Allowance for Next-Generation Mitomycin-Based Products Expected to Provide Protection Until December 2041

Fóruns

Nenhuma Discussão Encontrada

Criar Nova Discussão

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições